Summary
Only a subset of label excerpts (primarily Indications and Usage and limited dosing/interaction language) was provided. Many claims made by the AI (mechanism, QT risk language, side effects, administration frequency, formulation-specific details, and specific interaction cautions) cannot be verified against the supplied label text. Some claims (e.g., indication and permissive concomitant use) are supported by the provided excerpts.
Category Scores
Accurate Statements
Ranolazine extended-release tablets are a prescription antianginal medicine.
Supported directionally by Indications for treatment of chronic angina (Section 1 excerpt: “Ranexa is indicated for the treatment of chronic angina.”).
Ranolazine extended-release tablets are used to treat chronic (long-term) angina.
Section 1 excerpt: “Ranexa is indicated for the treatment of chronic angina.”
Ranolazine extended-release tablets should not be crushed or chewed.
Section 2.1 dosing excerpt: “Swallow Ranexa tablets whole; do not crush, break, or chew.”
Ranolazine may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.
Section 1 excerpt: “Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.”
Ranolazine can interact with other medicines that affect how it is processed in the body.
Section 7.1 excerpt: “Ranolazine is primarily metabolized by CYP3A and is a substrate of P-glycoprotein (P-gp).” and dose modification guidance with interacting drugs.
Ranolazine is primarily metabolized by CYP3A and is a substrate of P-glycoprotein (P-gp).
Section 7.1 excerpt: “Ranolazine is primarily metabolized by CYP3A and is a substrate of P-glycoprotein (P-gp).”
Do not use Ranexa with strong CYP3A inhibitors.
Section 7.1 excerpt: “Do not use Ranexa with strong CYP3A inhibitors …”
Unsupported Statements
Chronic angina is a type of chest pain caused by reduced blood flow to the heart.
No label excerpt provided defining chronic angina as reduced blood flow.
Ranolazine extended-release tablets are designed to release the drug slowly over time to maintain steadier drug levels.
No label excerpt provided describing extended-release design/steadier levels.
Ranolazine helps reduce angina symptoms by changing how the heart’s electrical activity and ion transport work.
No label excerpt provided describing mechanism of action at this level.
Ranolazine can improve the heart’s ability to function during reduced oxygen supply.
No label excerpt provided supporting this specific physiologic claim.
Ranolazine extended-release is taken by mouth as a once-daily extended-release tablet.
No label excerpt provided stating once-daily dosing for the extended-release tablets. Provided label dosing excerpt states initiation at 500 mg twice daily and titration to 1000 mg twice daily.
Commonly concerned side effects of ranolazine include dizziness.
No adverse reaction excerpt provided in the supplied text.
Commonly concerned side effects of ranolazine include headache.
No adverse reaction excerpt provided in the supplied text.
Commonly concerned side effects of ranolazine include constipation.
No adverse reaction excerpt provided in the supplied text.
Commonly concerned side effects of ranolazine include nausea.
No adverse reaction excerpt provided in the supplied text.
Commonly concerned side effects of ranolazine include sleepiness.
No adverse reaction excerpt provided in the supplied text.
A key safety concern with ranolazine is heart rhythm effects (QT interval prolongation).
No warnings/boxed warnings excerpt provided addressing QT interval prolongation.
Ranolazine interactions are especially with certain strong inhibitors of liver enzymes.
Provided label excerpt specifies strong CYP3A inhibitors and CYP3A metabolism; it does not characterize them as “liver enzymes” in this phrasing.
Strong inhibitors of liver enzymes that handle many drugs can increase ranolazine levels.
No label excerpt provided explicitly stating “increase levels” in this general way (though strong inhibitor avoidance is stated).
Increased ranolazine levels raise the risk of rhythm problems.
No warnings/QT or level-to-risk relationship excerpt provided.
Clinicians consider drug interactions and underlying heart conditions because of rhythm risk.
No label excerpt provided with clinician decision-making language or rhythm-risk linkage.
Extra caution is typical if a patient has a history of abnormal heart rhythms.
No warnings excerpt provided regarding abnormal heart rhythms.
Extra caution is typical if a patient has a history of QT prolongation.
No warnings excerpt provided regarding QT prolongation.
Extra caution is typical if a patient has significant liver impairment.
No hepatic impairment warnings/excerpts were provided.
Dose adjustments or closer monitoring may be needed for ranolazine depending on other risk factors and concurrent medicines.
While dose modification language exists (“Dose adjustments may be needed…”), the specific “closer monitoring” phrasing and broad “risk factors” are not directly supported by the provided excerpts.
Ranolazine is available in immediate-release formulations in some markets.
No formulation availability excerpt provided.
Extended-release dosing can reduce peak-trough fluctuations compared with immediate-release dosing.
No pharmacokinetic comparison excerpt provided.
The safety of combining ranolazine with other angina medicines depends on whether drugs run through the same metabolism pathways.
No label excerpt provided with this generalized “same metabolism pathways” statement (only specific CYP3A/P-gp-related interaction guidance provided).
Before starting or while taking ranolazine ER, it helps to review a history of QT prolongation or arrhythmias.
No warnings excerpt provided regarding QT prolongation/arrhythmias.
Before starting or while taking ranolazine ER, it helps to review liver disease.
No hepatic impairment/liver disease guidance excerpt provided.
Before starting or while taking ranolazine ER, it helps to review a complete list of medicines (including OTC drugs and supplements) to avoid harmful interactions.
No label excerpt provided advising reviewing OTC/supplements specifically.
Contradictions
Low
AI Statement
Ranolazine extended-release is taken by mouth as a once-daily extended-release tablet.
Label Reference
Section 2.1 excerpt: “Initiate Ranexa dosing at 500 mg twice daily and increase to 1000 mg twice daily…” (contradicts once-daily claim).
Important Omissions
Dose frequency and key dosing/titration details for Ranexa extended-release tablets (e.g., twice-daily initiation and titration) were not reflected in several claims (notably the once-daily claim) and could materially affect safe use.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The once-daily dosing claim conflicts with the provided label excerpt indicating twice-daily dosing, which is potentially significant for patient safety. Many other safety-related statements (QT risk, liver impairment caution, side effects) were not supported by the supplied label excerpts, limiting label alignment confidence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Incorrect dosing frequency claim (once-daily) conflicting with label excerpt (twice daily).
Suggested Improvement
Replace the once-daily administration claim with the label-supported dosing frequency/titration (initiate 500 mg twice daily, increase to 1000 mg twice daily as needed) and remove or qualify unsupported mechanism, QT/rhythm-risk, side-effect frequency, and liver/QT caution statements unless corresponding label excerpts are provided.